Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03118713
- Locations
- 🇰🇷
Site 11, Guri-si, Korea, Republic of
🇰🇷Site 01, Seoul, Korea, Republic of
🇰🇷Site 09, Seoul, Korea, Republic of
Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 6
- Registration Number
- NCT02985242
- Locations
- 🇩🇪
Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover, Hanover, Lower Saxony, Germany
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 45
- Registration Number
- NCT02973477
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 61
- Registration Number
- NCT02964572
- Locations
- 🇰🇷
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center, Seoul, Korea, Republic of
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Theracos
- Target Recruit Count
- 54
- Registration Number
- NCT02956044
- Locations
- 🇺🇸
Clinical Research Site, Evansville, Indiana, United States
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Theracos
- Target Recruit Count
- 426
- Registration Number
- NCT02769481
- Locations
- 🇪🇸
Research Site 3, Madrid, Spain
🇪🇸Research Site 2, Oviedo, Spain
🇪🇸Research Site, Valencia, Spain
SGLT2 Inhibition and Left Ventricular Mass
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 7
- Registration Number
- NCT02728453
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 25
- Registration Number
- NCT02694263
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
🇬🇧University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 40
- Registration Number
- NCT02649465
- Locations
- 🇯🇵
Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
- Conditions
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 506
- Registration Number
- NCT02630706
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.